FIM 4269

Drug Profile

FIM 4269

Alternative Names: FIM-4269

Latest Information Update: 27 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fimbrion Therapeutics
  • Developer Fimbrion Therapeutics; GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Urinary tract infections

Most Recent Events

  • 25 Oct 2016 Preclinical trials in Urinary tract infections (Prevention) in United Kingdom (PO)
  • 25 Oct 2016 Preclinical trials in Urinary tract infections (Prevention) in USA (PO)
  • 25 Oct 2016 Preclinical trials in Urinary tract infections in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top